title: Inferior outcomes of stage III T lymphoblastic lymphoma relative to stage IV lymphoma and T-acute lymphoblastic leukemia: long-term comparison of outcomes in the JACLS NHL T-98 and ALL T-97 protocols.
abstract: T cell lymphoblastic lymphoma (T-LBL) accounts for 30 % of all childhood non-Hodgkin's lymphomas (NHL) in Japan. Twenty-nine patients with T-LBL in stages III and IV were eligible for and enrolled in the JACLS NHL-T98 trial (1998-2002), and 72 patients with T-ALL were enrolled in the JACLS ALL-T97 trial (1997-2001). The 10-year overall survival (OS) (61.1 ± 11.5 %) and the 10-year event-free survival (EFS) (44.4 ± 11.7 %) of stage III LBL were lower than those of other diseases, and the OS and EFS were nearly the same when comparing stage IV LBL and ALL (OS: stage IV LBL, 80.0 ± 12.7 % vs. ALL, 80.2 ± 4.9 %; EFS: stage IV, LBL 70.0 ± 14.5 % vs. ALL, 70.7 ± 5.5 %). Outcomes were worse for stage III LBL than for stage IV LBL or T-ALL. Given that the treatment results of T-ALL and LBL stage IV did not differ when compared with previous reports, LBL stage III in Japanese children may differ from LBL stage III in children in other countries.
authors.affiliation: Department of Pediatrics, Sapporo Hokuyu Hospital, Higashi-Sapporo 6-6, Shiroishiku, Sapporo, 003-0006, Japan, r-koba@jacls.jp.
authors.forename: Ryoji
authors.initials: R
authors.lastname: Kobayashi
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Takimoto
authors.forename: Atsuko
authors.initials: A
authors.lastname: Nakazawa
authors.forename: Naoto
authors.initials: N
authors.lastname: Fujita
authors.forename: Ayumi
authors.initials: A
authors.lastname: Akazai
authors.forename: Kazumi
authors.initials: K
authors.lastname: Yamato
authors.forename: Makoto
authors.initials: M
authors.lastname: Yazaki
authors.forename: Takao
authors.initials: T
authors.lastname: Deguchi
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Hashii
authors.forename: Koji
authors.initials: K
authors.lastname: Kato
authors.forename: Naoki
authors.initials: N
authors.lastname: Hatakeyama
authors.forename: Keizo
authors.initials: K
authors.lastname: Horibe
authors.forename: Hiroki
authors.initials: H
authors.lastname: Hori
authors.forename: Megumi
authors.initials: M
authors.lastname: Oda
mesh_terms: D000293:Adolescent; D000954:Antigens, Surface / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D060830:Consolidation Chemotherapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016130:Immunophenotyping; D060828:Induction Chemotherapy; D060046:Maintenance Chemotherapy; D008297:Male; D009367:Neoplasm Staging; D063868:Patient Outcome Assessment; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology*; D011379:Prognosis; D012042:Registries; D016896:Treatment Outcome
chemical_list: D000954:Antigens, Surface